摘要
目的探讨使用苯溴马隆治疗痛风合并高尿酸血症的临床疗效。方法选择2018年12月至2021年12月在睢县中医院接受治疗的痛风合并高尿酸血症患者174人作为研究对象。依据随机数字表法进行分为对照组与观察组,各87例。对照组患者在常规干预基础上给予非布司他。观察组患者在常规干预基础上给予非布司他和苯溴马隆联合使用。对比两组的治疗效果。对比两组治疗前后的血液相关指标、痛风石情况、关节病变情况、生活质量。对比两组不良反应情况。结果观察组治疗效果分级优于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者的血尿酸、血肌酐、C反应蛋白、红细胞沉降率均降低,且观察组均低于对照组;两组患者痛风石数量、痛风石体积均减少,且观察组均低于对照组;两组患者发病关节数量、关节疼痛评分、关节肿胀评分均降低,且观察组评分均低于对照组;两组患者的QLQ-C30评分均增加,且观察组评分高于对照组,差异有统计学意义(P<0.05)。两组的用药不良反应发生率对比,差异无统计学意义(P>0.05)。结论苯溴马隆联合非布司他的方法治疗痛风合并高尿酸血症,可改善治疗效果,提升患者的血液相关指标,降低痛风石的体积和数量,改善关节病变,提升生活质量,具有良好安全性。
Objective To explore the clinical efficacy of benzbromarone in the treatment of gout with hyperuricemia.Methods A total of 174 patients with gout complicated with hyperuricemia who were treated in Suixian Hospital of traditional Chinese Medicine from December 2018 to December 2021 were selected as subjects.The group was divided into a control group and an observation group based on the random number table method,with 87 cases each.The patients in the control group were given non-budestar on the basis of routine intervention.The patients in the observation group were given the combined use of febutamol and benzbromarone on the basis of routine intervention.The therapeutic effects of the two groups were compared.The blood related indexes,gout stone,joint disease and quality of life of the two groups were compared before and after treatment.Compare the adverse drug reactions of the two groups.Results The treatment effect of the observation group was graded better than that of the control group,the difference is statistically significant(P<0.05).After treatment,the blood uric acid,blood creatinine,C-reactive protein and erythrocyte sedimentation rate of patients in both groups decreased,and the observation group was lower than the control group;the number of gout stones and the volume of gout stones of patients in both groups decreased,and the observation group was lower than the control group;the number of joints,joint pain score and joint swelling score of patients in both groups decreased,and the observation group was lower than the control group.The QLQ-C30 score of patients in both groups increased,and the observation group was higher than the control group,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in the two groups was not statistically significant(P>0.05).Conclusion The treatment of patients with gout and hyperuricemia with benzbromarone combined with fepristone can improve the treatment effect,improve the blood related indexes of patients,reduce the volume and quantity of gout stones,improve joint disease,improve the quality of life,and have good safety.
作者
白海霞
BAI Haixia(Department of Internal Medicine,Suixian Hospital of Traditional Chinese Medicine,Shangqiu Henan 476900,China)
出处
《临床研究》
2023年第6期66-69,共4页
Clinical Research
